Cargando…
Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries
ABSTRACT: The global spread of COVID-19 has raised the importance of pharmaceutical drug development as intractable and hot research. Developing new drug molecules to overcome any disease is a costly and lengthy process, but the process continues uninterrupted. The critical point to consider the dru...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536481/ https://www.ncbi.nlm.nih.gov/pubmed/34686947 http://dx.doi.org/10.1007/s11030-021-10326-z |
_version_ | 1784588015696347136 |
---|---|
author | Selvaraj, Chandrabose Chandra, Ishwar Singh, Sanjeev Kumar |
author_facet | Selvaraj, Chandrabose Chandra, Ishwar Singh, Sanjeev Kumar |
author_sort | Selvaraj, Chandrabose |
collection | PubMed |
description | ABSTRACT: The global spread of COVID-19 has raised the importance of pharmaceutical drug development as intractable and hot research. Developing new drug molecules to overcome any disease is a costly and lengthy process, but the process continues uninterrupted. The critical point to consider the drug design is to use the available data resources and to find new and novel leads. Once the drug target is identified, several interdisciplinary areas work together with artificial intelligence (AI) and machine learning (ML) methods to get enriched drugs. These AI and ML methods are applied in every step of the computer-aided drug design, and integrating these AI and ML methods results in a high success rate of hit compounds. In addition, this AI and ML integration with high-dimension data and its powerful capacity have taken a step forward. Clinical trials output prediction through the AI/ML integrated models could further decrease the clinical trials cost by also improving the success rate. Through this review, we discuss the backend of AI and ML methods in supporting the computer-aided drug design, along with its challenge and opportunity for the pharmaceutical industry. GRAPHIC ABSTRACT: [Image: see text] From the available information or data, the AI and ML based prediction for the high throughput virtual screening. After this integration of AI and ML, the success rate of hit identification has gained a momentum with huge success by providing novel drugs. |
format | Online Article Text |
id | pubmed-8536481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85364812021-10-25 Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries Selvaraj, Chandrabose Chandra, Ishwar Singh, Sanjeev Kumar Mol Divers Short Review ABSTRACT: The global spread of COVID-19 has raised the importance of pharmaceutical drug development as intractable and hot research. Developing new drug molecules to overcome any disease is a costly and lengthy process, but the process continues uninterrupted. The critical point to consider the drug design is to use the available data resources and to find new and novel leads. Once the drug target is identified, several interdisciplinary areas work together with artificial intelligence (AI) and machine learning (ML) methods to get enriched drugs. These AI and ML methods are applied in every step of the computer-aided drug design, and integrating these AI and ML methods results in a high success rate of hit compounds. In addition, this AI and ML integration with high-dimension data and its powerful capacity have taken a step forward. Clinical trials output prediction through the AI/ML integrated models could further decrease the clinical trials cost by also improving the success rate. Through this review, we discuss the backend of AI and ML methods in supporting the computer-aided drug design, along with its challenge and opportunity for the pharmaceutical industry. GRAPHIC ABSTRACT: [Image: see text] From the available information or data, the AI and ML based prediction for the high throughput virtual screening. After this integration of AI and ML, the success rate of hit identification has gained a momentum with huge success by providing novel drugs. Springer International Publishing 2021-10-23 2022 /pmc/articles/PMC8536481/ /pubmed/34686947 http://dx.doi.org/10.1007/s11030-021-10326-z Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Short Review Selvaraj, Chandrabose Chandra, Ishwar Singh, Sanjeev Kumar Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title | Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title_full | Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title_fullStr | Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title_full_unstemmed | Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title_short | Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
title_sort | artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536481/ https://www.ncbi.nlm.nih.gov/pubmed/34686947 http://dx.doi.org/10.1007/s11030-021-10326-z |
work_keys_str_mv | AT selvarajchandrabose artificialintelligenceandmachinelearningapproachesfordrugdesignchallengesandopportunitiesforthepharmaceuticalindustries AT chandraishwar artificialintelligenceandmachinelearningapproachesfordrugdesignchallengesandopportunitiesforthepharmaceuticalindustries AT singhsanjeevkumar artificialintelligenceandmachinelearningapproachesfordrugdesignchallengesandopportunitiesforthepharmaceuticalindustries |